Encouraging Patients with Overactive Bladder to Seek Treatment Through Time To Go Campaign

Encouraging Awareness for Overactive Bladder: The Time To Go™ Campaign

Sumitomo Pharma America, Inc. (SMPA) has partnered with actress and overactive bladder (OAB) patient advocate Holly Robinson Peete for the third consecutive year to promote the Time To Go™ campaign. This initiative aims to raise awareness about the challenges posed by OAB, which affects approximately 33 million Americans. Through this campaign, Peete and fellow patients share their experiences with OAB and discuss the importance of seeking treatment.

Holly Robinson Peete, known for her influential voice in health advocacy, highlights the significant impacts of OAB symptoms on daily life, which can include frequent urination and sudden urges that disrupt personal and professional activities. Despite the prevalence of this condition, many individuals suffer in silence due to embarrassment. The Time To Go campaign is designed to empower individuals to speak up about their symptoms, transforming what could be a solitary burden into a communal experience of understanding and support.

The campaign also emphasizes the benefits of the medication GEMTESA® (vibegron), which has been portrayed by Peete as a game changer in her personal journey with OAB. In her testimony, she reported a marked reduction in her symptoms after starting a consistent treatment regimen with GEMTESA. This change in her quality of life now allows her to engage in activities she enjoys without the constant worry of finding a bathroom.

By partnering with real-life patients Diane and Dar, who are involved in the GEMTESA Go-Getters ambassador program, the campaign aims to foster open discussions about OAB and the treatment options available. Their candid conversations are featured on the Time To Go website, providing a relatable platform for others experiencing similar challenges. The emotional support derived from hearing others' stories resonates deeply, serving as a reminder that no one is alone in their struggles with OAB.

In a statement, Peete expressed her enthusiasm for this continuing partnership, stating, "I’m excited to continue this partnership with SMPA to encourage people with OAB to take action." Her personal journey and successful treatment with GEMTESA serve not only as motivation for herself but also encourage others to consider seeking treatment. Many patients may feel isolated in their experiences, particularly when discussing urinary conditions, but Peete's advocacy seeks to normalize these conversations.

According to Alana Darden Powell, Vice President of Marketing, Urology at SMPA, the campaign aims to break down the stigma surrounding OAB. She praises Peete's influence in promoting awareness and notes that it is vital for patients to discuss their symptoms with healthcare professionals to determine appropriate treatment options.

For individuals dealing with OAB, the Time To Go campaign encourages you to approach your doctor for a diagnosis and explore available treatments. For more information on OAB management and GEMTESA, visit TimeToGo.com. As awareness surrounding this condition grows, so does the opportunity for effective treatment, allowing people to reclaim their lives from the disruption of OAB.

About Overactive Bladder

Overactive bladder is characterized by involuntary bladder contractions, leading to symptoms like sudden urges to urinate, urgent incontinence, and frequent urination. These symptoms can be distressing, significantly affecting the quality of life for those who experience them.

About GEMTESA®

GEMTESA is a prescription medication specifically designed to treat OAB symptoms, allowing patients to manage their condition effectively. While it remains essential for patients to consult with healthcare providers to identify personalized treatment plans, GEMTESA has emerged as a promising option for many individuals seeking relief and renewed quality of life.

In conclusion, the Time To Go campaign not only fosters awareness about OAB but also encourages community and support among those affected. With advocates like Holly Robinson Peete leading the charge, there's hope for wider recognition and understanding of this often stigma-ridden condition.